<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961844</url>
  </required_header>
  <id_info>
    <org_study_id>DC-004</org_study_id>
    <secondary_id>2008-006253-41</secondary_id>
    <nct_id>NCT00961844</nct_id>
  </id_info>
  <brief_title>Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma</brief_title>
  <official_title>Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steinar Aamdal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial the investigators want to combine chemotherapy with immunotherapy by giving the&#xD;
      patients Temozolomide, before vaccination. The investigators have also included hTERT and&#xD;
      survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell&#xD;
      expansion after lymphodepletion for the patients who show an immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Logistical problems&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toxicity of vaccination with DC transfected h-TERT mRNA, survivin mRNA and tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion in patients with metastatic malignant melanoma.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunological responses, time to disease progression and survival time.</measure>
    <time_frame>5 years of follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Metastatic Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>DC vaccine + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion</intervention_name>
    <arm_group_label>DC vaccine + Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>DC vaccine + Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified malignant melanoma with measurable (according to RECIST),&#xD;
             unresectable metastases (Stage III or Stage IV M1a-c as defined by criteria of the&#xD;
             AJCC Cancer Staging Manual, 6 th. Edition 2002). Patients with a melanoma of an&#xD;
             unknown primary site are eligible.&#xD;
&#xD;
          -  Preferably accessible tumor tissue with enough volume and quality for vaccine&#xD;
             production (extraction of tumor mRNA)&#xD;
&#xD;
          -  Must be at least 18 years of age&#xD;
&#xD;
          -  Must be ambulatory with a ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Negative MRI of the brain&#xD;
&#xD;
          -  Must have lab values as the following:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  Hb ≥ 9 g/dL (≥ 5.6 mmol/L)&#xD;
&#xD;
               -  Creatinine ≤ 140 μmol/L (1.6 mg/dL); if borderline, the creatinine clearance ≥ 40&#xD;
                  mL/min&#xD;
&#xD;
               -  Bilirubin &lt; 20% above the upper limit of normal&#xD;
&#xD;
               -  ASAT and ALAT ≤ 2.5 the upper limit of normal&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/L&#xD;
&#xD;
          -  If the patient is female, she must practice adequate contraception during the study&#xD;
             treatment&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented according to ICH/GCP, and national/local&#xD;
             regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient suffers from an ocular- or mucous membrane melanoma&#xD;
&#xD;
          -  History of prior malignancy other than melanoma, except for curatively treated basal&#xD;
             cell or squamous cell carcinoma of the skin and cervix cancer stage 1B or effectively&#xD;
             treated malignancy that has been in remission for over 5 years and is highly likely to&#xD;
             have been cured.&#xD;
&#xD;
          -  Active systemic infections requiring intravenous antibiotics, coagulation disorders or&#xD;
             other major medical illnesses of the cardiovascular, respiratory or immune systems. PI&#xD;
             shall make the final determination regarding appropriateness of enrollment&#xD;
&#xD;
          -  Autoimmune disease currently being treated with systemic steroids Version no. 3, 18&#xD;
             June 2009 Page 17 of 50&#xD;
&#xD;
          -  Adverse reactions to vaccines such as anaphylaxis or other serious reactions&#xD;
&#xD;
          -  History of immunodeficiency or autoimmune disease such as rheumatoid arthritis,&#xD;
             systemic lupus erythematosus, scleroderma, polymyositis-dermatomyositis, juvenile&#xD;
             onset insulin dependent diabetes, or a vasculitic syndrome&#xD;
&#xD;
          -  Positive for HIV, Hepatitis B and C and Syphilis (treponema pallidum)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  If the patient has received any prior anti-cancer treatment, including radiotherapy,&#xD;
             chemotherapy immunotherapy and/or immunomodulating agents, this must have been stopped&#xD;
             at least 4 weeks before first study treatment administration.&#xD;
&#xD;
          -  Chemotherapy, glucocorticosteroids or other potentially immune-suppressive therapy&#xD;
             that has been administered within 4 weeks prior to vaccination&#xD;
&#xD;
          -  No treatment with dacarbazine or temozolomide at any time prior to study entry&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steinar Aamdal, M.D PhD Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital - Norwegian Radium Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital, Department of Clinical Cancer Research</name>
      <address>
        <city>Oslo</city>
        <state>Montebello</state>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Steinar Aamdal</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

